Abstract
Exenatide (Byetta), an injectable glucagon-like peptide-1 (GLP-1) receptor agonist, is useful in managing patients with type 2 diabetes, because it stimulates glucose-dependent insulin secretion, reduces glucagon secretion, slows gastric emptying, and attenuates food intake. A once-weekly injectable form of exenatide is more effective than the currently FDA-approved twice-daily exenatide formulation …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
